Agomab

Agomab is a pioneering biotechnology research company dedicated to developing innovative treatments for fibrosis, tissue repair, and organ function restoration. Leveraging extensive expertise in growth factor biology, Agomab is committed to translating cutting-edge scientific insights into groundbreaking therapies with the potential to modify disease progression in severe organ failure and fibrotic diseases.

With a focus on robust drug development and a long-term corporate vision, Agomab is building a diverse clinical pipeline of differentiated programs. The company's primary address is in Antwerp, BE, with additional locations in Torino, IT, and A Coruna, ES, reflecting its global reach and commitment to addressing critical medical needs. Agomab aims to improve patient outcomes and transform the treatment landscape for fibrotic conditions.

Agomab is poised to make significant advancements in the field of biotechnology. The information regarding Agomab will be completed soon with the support of the company’s management. We invite the manager of Agomab to create a customized and exclusive company showcase and product listing on our platform.